Last reviewed · How we verify
NCT05356520
Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction
NA trial testing Endoscopy Ivor-lewis in Siewert Type II Adenocarcinoma of Esophagogastric Junction in 212 participants. Currently enrolling.
31 May 2025
Quick facts
| Lead sponsor | Xijing Hospital of Digestive Diseases |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 212 |
| Start date | 1 May 2022 |
| Primary completion | 31 May 2025 |
| Estimated completion | 31 May 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Endoscopy Ivor-lewis
- Laparoscopic transabdominal enlarged gastrectomy
Conditions studied
- Siewert Type II Adenocarcinoma of Esophagogastric Junction — all drugs for Siewert Type II Adenocarcinoma of Esophagogastric Junction →
Sponsor
Xijing Hospital of Digestive Diseases
Who can join
Adults 18 to 75, any sex, with Siewert Type II Adenocarcinoma of Esophagogastric Junction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The incidence of esophagogastric junction has been increasing in recent years, and surgery is an important method for the treatment of adenoma at the esophagogastric junction. Currently, there is a great controversy about the surgical method of Siewert II, mainly choosing the right chest or the left chest for thoracic surgery. Therefore, it is of great significance to further study the surgical methods of Siewert II esophagogastric junction adenoma. Objective: To compare the safety, feasibility, and clinical efficacy of endoscopic Ivor-Lewis versus laparoscopic extended abdominal gastrectomy for Siewert type Ⅱadenocarcinoma at the resectable esophagogastric junction.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparison of thoracoabdominal versus abdominal-transhiatal surgical approaches in Siewert type II adenocarcinoma at the esophagogastric junction: Protocol for a prospective multicenter randomized controlled trial.
Yue C, Mo Z, Wu X, Wang Y, et al · · 2023 · PMID 37064105 · DOI 10.3389/fonc.2023.1091615
Verify or expand the search:
- PubMed search for NCT05356520
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Siewert Type II Adenocarcinoma of Esophagogastric Junction
Currently open trials in the same condition.
- NCT07441785 — Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esopha · recruiting
- NCT06044311 — Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma · Phase 2 · recruiting
- NCT06644352 — Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma · NA · recruiting
Other Xijing Hospital of Digestive Diseases trials
Trials by the same sponsor.
- NCT07401303 — Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time · NA · not yet recruiting
- NCT07296458 — FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy · Phase 3 · recruiting
- NCT07129460 — Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia · Phase 4 · not yet recruiting
- NCT07182890 — Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
- NCT07187492 — Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05356520 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital of Digestive Diseases
- Last refreshed: 8 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05356520.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing